3 Vaccine Latecomers That Could Double Your Money
It's easy to be impressed when looking at the share gains of vaccine leaders Moderna and BioNTech. Shares of the biotech giants have soared more than 100% and 200%, respectively, this year. And they could climb higher as sales of boosters keep revenue rolling in next year. Experts predict the coronavirus will stick around -- so a potential end to the pandemic wouldn't necessarily equal an end to the need for vaccination.
But the main players aren't the only game in town. In fact, you may see bigger returns from an investment in a smaller biotech company that hasn't yet reached the vaccine finish line. Positive clinical trial reports or regulatory submissions could be major catalysts. Let's check out three vaccine latecomers that could possibly double your money.
Image source: Getty Images.
Source Fool.com
